APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chimeric Antigen Receptor (CAR) T-Cell Therapy

Compare research editions
View pricing & licenses

Selected research

Industry Research

Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Research Report 2026

20 December 2025121 pages

Choose your research edition.

Industry ResearchChimeric Antigen Receptor (CAR) T-Cell Therapy Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Chimeric Antigen Receptor (CAR) T-Cell Therapy market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Chimeric Antigen Receptor (CAR) T-Cell Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Chimeric Antigen Receptor (CAR) T-Cell Therapy market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Chimeric Antigen Receptor (CAR) T-Cell Therapy market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Chimeric Antigen Receptor (CAR) T-Cell Therapy include Allogene Therapeutics, Autolus Therapeutics, Bluebird Bio, CARsgen Therapeutics, Cellectis, Celyad, FOSUNKite, JW Therapeutics and Mustang Bio, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

Read the full market overview

This report quantifies the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Chimeric Antigen Receptor (CAR) T-Cell Therapy.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Company

Allogene Therapeutics

Autolus Therapeutics

Bluebird Bio

CARsgen Therapeutics

Cellectis

Celyad

FOSUNKite

JW Therapeutics

Mustang Bio

Sorrento Therapeutics

Bristol-Myers Squibb

Gilead Sciences

Novartis

J & J

Chimeric Antigen Receptor (CAR) T-Cell Therapy Segment by Type

CD19-targeted

BCMA-targeted

Chimeric Antigen Receptor (CAR) T-Cell Therapy Segment by Application

Lymphoma

Multiple Myeloma

Chimeric Antigen Receptor (CAR) T-Cell Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chimeric Antigen Receptor (CAR) T-Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chimeric Antigen Receptor (CAR) T-Cell Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Chimeric Antigen Receptor (CAR) T-Cell Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue Market Share by Type (2021-2026) Table 7. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue Market Share by Type (2027-2032) Table 9. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue Market Share by Application (2021-2026) Table 11. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue Market Share by Application (2027-2032) Table 13. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Share by Region (2021-2026) Table 16. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Share by Region (2027-2032) Table 18. Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Trends Table 19. Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Drivers Table 20. Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Opportunities and Challenges Table 21. Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Restraints Table 22. Global Top Chimeric Antigen Receptor (CAR) T-Cell Therapy Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue Market Share by Players (2021-2026) Table 24. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Chimeric Antigen Receptor (CAR) T-Cell Therapy, Headquarters and Area Served Table 26. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2027-2032) & (US$ Million) Table 45. Allogene Therapeutics Company Information Table 46. Allogene Therapeutics Business Overview Table 47. Allogene Therapeutics Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) & (US$ Million) Table 48. Allogene Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 49. Allogene Therapeutics Recent Developments Table 50. Autolus Therapeutics Company Information Table 51. Autolus Therapeutics Business Overview Table 52. Autolus Therapeutics Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) & (US$ Million) Table 53. Autolus Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 54. Autolus Therapeutics Recent Developments Table 55. Bluebird Bio Company Information Table 56. Bluebird Bio Business Overview Table 57. Bluebird Bio Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) & (US$ Million) Table 58. Bluebird Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 59. Bluebird Bio Recent Developments Table 60. CARsgen Therapeutics Company Information Table 61. CARsgen Therapeutics Business Overview Table 62. CARsgen Therapeutics Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) & (US$ Million) Table 63. CARsgen Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 64. CARsgen Therapeutics Recent Developments Table 65. Cellectis Company Information Table 66. Cellectis Business Overview Table 67. Cellectis Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) & (US$ Million) Table 68. Cellectis Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 69. Cellectis Recent Developments Table 70. Celyad Company Information Table 71. Celyad Business Overview Table 72. Celyad Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) & (US$ Million) Table 73. Celyad Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 74. Celyad Recent Developments Table 75. FOSUNKite Company Information Table 76. FOSUNKite Business Overview Table 77. FOSUNKite Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) & (US$ Million) Table 78. FOSUNKite Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 79. FOSUNKite Recent Developments Table 80. JW Therapeutics Company Information Table 81. JW Therapeutics Business Overview Table 82. JW Therapeutics Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) & (US$ Million) Table 83. JW Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 84. JW Therapeutics Recent Developments Table 85. Mustang Bio Company Information Table 86. Mustang Bio Business Overview Table 87. Mustang Bio Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) & (US$ Million) Table 88. Mustang Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 89. Mustang Bio Recent Developments Table 90. Sorrento Therapeutics Company Information Table 91. Sorrento Therapeutics Business Overview Table 92. Sorrento Therapeutics Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) & (US$ Million) Table 93. Sorrento Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 94. Sorrento Therapeutics Recent Developments Table 95. Bristol-Myers Squibb Company Information Table 96. Bristol-Myers Squibb Business Overview Table 97. Bristol-Myers Squibb Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) & (US$ Million) Table 98. Bristol-Myers Squibb Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 99. Bristol-Myers Squibb Recent Developments Table 100. Gilead Sciences Company Information Table 101. Gilead Sciences Business Overview Table 102. Gilead Sciences Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) & (US$ Million) Table 103. Gilead Sciences Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 104. Gilead Sciences Recent Developments Table 105. Novartis Company Information Table 106. Novartis Business Overview Table 107. Novartis Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) & (US$ Million) Table 108. Novartis Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 109. Novartis Recent Developments Table 110. J & J Company Information Table 111. J & J Business Overview Table 112. J & J Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) & (US$ Million) Table 113. J & J Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio Table 114. J & J Recent Developments Table 115. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Image Figure 5. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Share by Type: 2025 VS 2032 Figure 7. CD19-targeted Product Figure 8. BCMA-targeted Product Figure 9. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Share by Application: 2025 VS 2032 Figure 11. Lymphoma Product Figure 12. Multiple Myeloma Product Figure 13. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 14. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Share by Region: 2025 VS 2032 Figure 16. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Share by Players in 2025 Figure 17. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Manufacturers Established Date Figure 18. Global Top 5 and 10 Chimeric Antigen Receptor (CAR) T-Cell Therapy Players Market Share by Revenue in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 21. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Share by Country (2021-2032) Figure 22. United States Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 23. Canada Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 24. Mexico Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Share by Country (2021-2032) Figure 25. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 26. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Share by Country (2021-2032) Figure 27. Germany Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 28. France Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. U.K. Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. Italy Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Spain Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. Russia Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Netherlands Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Nordic Countries Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Share by Country (2021-2032) Figure 37. China Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 38. Japan Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. South Korea Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. India Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. India Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Share by Country (2021-2032) Figure 42. Australia Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 43. China Taiwan Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 44. Southeast Asia Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Share by Country (2021-2032) Figure 47. Brazil Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 48. Argentina Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 49. Chile Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 50. Colombia Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. Peru Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Allogene Therapeutics Revenue Growth Rate in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) Figure 53. Autolus Therapeutics Revenue Growth Rate in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) Figure 54. Bluebird Bio Revenue Growth Rate in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) Figure 55. CARsgen Therapeutics Revenue Growth Rate in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) Figure 56. Cellectis Revenue Growth Rate in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) Figure 57. Celyad Revenue Growth Rate in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) Figure 58. FOSUNKite Revenue Growth Rate in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) Figure 59. JW Therapeutics Revenue Growth Rate in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) Figure 60. Mustang Bio Revenue Growth Rate in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) Figure 61. Sorrento Therapeutics Revenue Growth Rate in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) Figure 62. Bristol-Myers Squibb Revenue Growth Rate in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) Figure 63. Gilead Sciences Revenue Growth Rate in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) Figure 64. Novartis Revenue Growth Rate in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026) Figure 65. J & J Revenue Growth Rate in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)

Scope & coverage.

Types
  • CD19-targeted
  • BCMA-targeted
Applications
  • Lymphoma
  • Multiple Myeloma
Companies covered
  • Allogene Therapeutics
  • Autolus Therapeutics
  • Bluebird Bio
  • CARsgen Therapeutics
  • Cellectis
  • Celyad
  • FOSUNKite
  • JW Therapeutics
  • Mustang Bio
  • Sorrento Therapeutics
  • Bristol-Myers Squibb
  • Gilead Sciences
  • Novartis
  • J & J

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  4. 2.2.2 CD19-targeted
  5. 2.2.3 BCMA-targeted
  6. 2.3 Chimeric Antigen Receptor (CAR) T-Cell Therapy by Application
  7. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  8. 2.3.2 Lymphoma
  9. 2.3.3 Multiple Myeloma
  10. 2.4 Assumptions and Limitations
3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Breakdown Data by Type
  1. 3.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Historic Market Size by Type (2021-2026)
  2. 3.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecasted Market Size by Type (2027-2032)
4 Chimeric Antigen Receptor (CAR) T-Cell Therapy Breakdown Data by Application
  1. 4.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Historic Market Size by Application (2021-2026)
  2. 4.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
  1. 5.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Perspective (2021-2032)
  2. 5.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Growth Trends by Region
  3. 5.2.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Region: 2021 VS 2025 VS 2032
  4. 5.2.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy Historic Market Size by Region (2021-2026)
  5. 5.2.3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecasted Market Size by Region (2027-2032)
  6. 5.3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Dynamics
  7. 5.3.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Trends
  8. 5.3.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Drivers
  9. 5.3.3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Challenges
  10. 5.3.4 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Restraints
6 Market Competitive Landscape by Players
  1. 6.1 Global Top Chimeric Antigen Receptor (CAR) T-Cell Therapy Players by Revenue
  2. 6.1.1 Global Top Chimeric Antigen Receptor (CAR) T-Cell Therapy Players by Revenue (2021-2026)
  3. 6.1.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue Market Share by Players (2021-2026)
  4. 6.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Players Ranking, 2023 VS 2024 VS 2025
  5. 6.3 Global Key Players of Chimeric Antigen Receptor (CAR) T-Cell Therapy Head Office and Area Served
  6. 6.4 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Players, Product Type & Application
  7. 6.5 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Manufacturers Established Date
  8. 6.6 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market CR5 and HHI
  9. 6.7 Global Players Mergers & Acquisition
7 North America
  1. 7.1 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (2021-2032)
  2. 7.2 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 7.3 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2021-2026)
  4. 7.4 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2027-2032)
  5. 7.5 United States
  6. 7.5 United States
  7. 7.6 Canada
  8. 7.7 Mexico
8 Europe
  1. 8.1 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (2021-2032)
  2. 8.2 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 8.3 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2021-2026)
  4. 8.4 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2027-2032)
  5. 8.5 Germany
  6. 8.6 France
  7. 8.7 U.K.
  8. 8.8 Italy
  9. 8.9 Spain
  10. 8.10 Russia
  11. 8.11 Netherlands
  12. 8.12 Nordic Countries
9 Asia-Pacific
  1. 9.1 Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (2021-2032)
  2. 9.2 Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 9.3 Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2021-2026)
  4. 9.4 Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2027-2032)
  5. 9.5 China
  6. 9.6 Japan
  7. 9.7 South Korea
  8. 9.8 India
  9. 9.9 Australia
  10. 9.10 China Taiwan
  11. 9.11 Southeast Asia
10 South America
  1. 10.1 South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (2021-2032)
  2. 10.2 South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 10.3 South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2021-2026)
  4. 10.4 South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2027-2032)
  5. 10.5 Brazil
  6. 10.6 Argentina
  7. 10.7 Chile
  8. 10.8 Colombia
  9. 10.9 Peru
11 Middle East & Africa
  1. 11.1 Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (2021-2032)
  2. 11.2 Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 11.3 Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2021-2026)
  4. 11.4 Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2027-2032)
  5. 11.5 Saudi Arabia
  6. 11.6 Israel
  7. 11.7 United Arab Emirates
  8. 11.8 Turkey
  9. 11.9 Iran
  10. 11.10 Egypt
12 Players Profiled
  1. 12.1 Allogene Therapeutics
  2. 12.1.1 Allogene Therapeutics Company Information
  3. 12.1.2 Allogene Therapeutics Business Overview
  4. 12.1.3 Allogene Therapeutics Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
  5. 12.1.4 Allogene Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  6. 12.1.5 Allogene Therapeutics Recent Developments
  7. 12.2 Autolus Therapeutics
  8. 12.2.1 Autolus Therapeutics Company Information
  9. 12.2.2 Autolus Therapeutics Business Overview
  10. 12.2.3 Autolus Therapeutics Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
  11. 12.2.4 Autolus Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  12. 12.2.5 Autolus Therapeutics Recent Developments
  13. 12.3 Bluebird Bio
  14. 12.3.1 Bluebird Bio Company Information
  15. 12.3.2 Bluebird Bio Business Overview
  16. 12.3.3 Bluebird Bio Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
  17. 12.3.4 Bluebird Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  18. 12.3.5 Bluebird Bio Recent Developments
  19. 12.4 CARsgen Therapeutics
  20. 12.4.1 CARsgen Therapeutics Company Information
  21. 12.4.2 CARsgen Therapeutics Business Overview
  22. 12.4.3 CARsgen Therapeutics Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
  23. 12.4.4 CARsgen Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  24. 12.4.5 CARsgen Therapeutics Recent Developments
  25. 12.5 Cellectis
  26. 12.5.1 Cellectis Company Information
  27. 12.5.2 Cellectis Business Overview
  28. 12.5.3 Cellectis Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
  29. 12.5.4 Cellectis Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  30. 12.5.5 Cellectis Recent Developments
  31. 12.6 Celyad
  32. 12.6.1 Celyad Company Information
  33. 12.6.2 Celyad Business Overview
  34. 12.6.3 Celyad Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
  35. 12.6.4 Celyad Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  36. 12.6.5 Celyad Recent Developments
  37. 12.7 FOSUNKite
  38. 12.7.1 FOSUNKite Company Information
  39. 12.7.2 FOSUNKite Business Overview
  40. 12.7.3 FOSUNKite Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
  41. 12.7.4 FOSUNKite Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  42. 12.7.5 FOSUNKite Recent Developments
  43. 12.8 JW Therapeutics
  44. 12.8.1 JW Therapeutics Company Information
  45. 12.8.2 JW Therapeutics Business Overview
  46. 12.8.3 JW Therapeutics Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
  47. 12.8.4 JW Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  48. 12.8.5 JW Therapeutics Recent Developments
  49. 12.9 Mustang Bio
  50. 12.9.1 Mustang Bio Company Information
  51. 12.9.2 Mustang Bio Business Overview
  52. 12.9.3 Mustang Bio Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
  53. 12.9.4 Mustang Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  54. 12.9.5 Mustang Bio Recent Developments
  55. 12.10 Sorrento Therapeutics
  56. 12.10.1 Sorrento Therapeutics Company Information
  57. 12.10.2 Sorrento Therapeutics Business Overview
  58. 12.10.3 Sorrento Therapeutics Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
  59. 12.10.4 Sorrento Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  60. 12.10.5 Sorrento Therapeutics Recent Developments
  61. 12.11 Bristol-Myers Squibb
  62. 12.11.1 Bristol-Myers Squibb Company Information
  63. 12.11.2 Bristol-Myers Squibb Business Overview
  64. 12.11.3 Bristol-Myers Squibb Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
  65. 12.11.4 Bristol-Myers Squibb Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  66. 12.11.5 Bristol-Myers Squibb Recent Developments
  67. 12.12 Gilead Sciences
  68. 12.12.1 Gilead Sciences Company Information
  69. 12.12.2 Gilead Sciences Business Overview
  70. 12.12.3 Gilead Sciences Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
  71. 12.12.4 Gilead Sciences Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  72. 12.12.5 Gilead Sciences Recent Developments
  73. 12.13 Novartis
  74. 12.13.1 Novartis Company Information
  75. 12.13.2 Novartis Business Overview
  76. 12.13.3 Novartis Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
  77. 12.13.4 Novartis Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  78. 12.13.5 Novartis Recent Developments
  79. 12.14 J & J
  80. 12.14.1 J & J Company Information
  81. 12.14.2 J & J Business Overview
  82. 12.14.3 J & J Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
  83. 12.14.4 J & J Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
  84. 12.14.5 J & J Recent Developments
13 Report Conclusion
    14 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst